Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
It is yet another burden layered on top of their already-daunting fight against cancer, said Dr. Paus.
- It is yet another burden layered on top of their already-daunting fight against cancer, said Dr. Paus.
- Ailerons vision is to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy.
- We look forward to our anticipated data readouts from that trial later this year and into 2023.
- Aileron previously conducted in vitro studies showing that ALRN-6924 protected human fibroblasts in cell culture from multiple chemotherapies, but not p53-mutant breast cancer cells.